

Ref: FOIA Reference 2019/20-319

Royal Stoke University Hospital
Quality, Safety and Compliance Department
Newcastle Road
Stoke-on-Trent
Staffordshire
ST4 6QG

Date: 13th September 2019

Email foi@uhn.nhs.uk

Dear

I am writing in response to your email dated 2nd September 2019 requesting information under the Freedom of Information Act (2000) regarding bone metastases.

As of 1st November 2014 University Hospitals of North Midlands NHS Trust (UHNM) manages two hospital sites – Royal Stoke University Hospital, and County Hospital (Stafford). Therefore the response below is for the two sites combined from that date where appropriate.

Q1 Within your health Trust how many metastatic breast cancer patients are currently [within the past 6 months] being treated, with any therapy, surgery or palliative care.

A1 UHNM had thirty nine (39) breast cancer patients who received treatment (any therapy, surgery or palliative care) for distant recurrence of cancer (metastatic disease) during the period 1st January 2019 to 30th June 2019.

Q2 Within your health Trust how many breast cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonafos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A2 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However, as the Trust is committed to openness and transparency we can band some of the numbers of being less than 5.

This exemption is an absolute exemption and therefore no consideration of the public interest test is required. Please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonafos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = <5
- denosumab (Xgeva) = 85

Q3 Within your health Trust how many breast cancer patients are currently [within the past 6 months] being treated with adjuvant therapy with the following treatments;

- disodium pamidronate (Aredia)
- ibandronic acid or ibandronate (Bondronat)
- sodium clodronate (Bonefos, Clasteon, Loron)
- Zoledronic acid or zoledronate (Zometa)

A3 Please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonefos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = 184

Q4 Within your health Trust how many metastatic lung cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

A4 UHNM had twenty five (25) lung patients who received treatment (any therapy, surgery or palliative care) for distant recurrence of cancer (metastatic disease) during the period 1st January 2019 to 30th June 2019

Q5 Within your health Trust how many lung cancer patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- disodium pamidronate (Aredia)
- ibandronic acid or ibandronate (Bondronat)
- sodium clodronate (Bonefos, Clasteon, Loron)
- zoledronic acid or zoledronate (Zometa)
- denosumab (Xgeva)

A5 We are unable to provide some of the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI Act. *Personal information*. However as the Trust is committed to openness and transparency we can band some of the numbers of being less than 5.

This exemption is an absolute exemption and therefore no consideration of the public interest test is required. Please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonefos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = <5
- denosumab (Xgeva) = 25

Q6 Within your health Trust how many metastatic renal cell cancer patients are currently [within the past 6 months] being treated with any therapy, surgery or palliative care.

A6 We are unable to provide the information you require in the requested format as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under Data Protection Act 2018. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the FOI

Act. *Personal information*. However as the Trust is committed to openness and transparency we can band the numbers of being less than 5.

This exemption is an absolute exemption and therefore no consideration of the public interest test is required.

Q7 Within your health Trust how many renal cell carcinoma [RCC] patients are currently [within the past 6 months] being treated for bone metastases with the following treatments;

- **disodium pamidronate (Aredia)**
- **ibandronic acid or ibandronate (Bondronat)**
- **sodium clodronate (Bonafos, Clasteon, Loron)**
- **zoledronic acid or zoledronate (Zometa)**
- **denosumab (Xgeva)**

A7 Please see below:

- disodium pamidronate (Aredia) = 0
- ibandronic acid or ibandronate (Bondronat) = 0
- sodium clodronate (Bonafos, Clasteon, Loron) = 0
- zoledronic acid or zoledronate (Zometa) = 0
- denosumab (Xgeva) = 7

*Please note that any individuals identified do not give consent for their personal data to be processed for the purposes of direct marketing.

UHNM NHS Trust is a public sector body and governed by EU law. FOI requestors should note that any new Trust requirements over the EU threshold will be subject to these regulations and will be advertised for open competition accordingly.

Where the Trust owns the copyright in information provided, you may re-use the information in line with the conditions set out in the Open Government Licence v3 which is available at <http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>. Where information was created by third parties, you should contact them directly for permission to re-use the information.

An anonymised copy of this request can be found on the Trust's disclosure log, please note that all requests can be found at the following link: <http://www.uhnm.nhs.uk/aboutus/Statutory-Policies-and-Procedures/Pages/Freedom-of-Information-Disclosure-Log.aspx>

This letter confirms the completion of this request. A log of this request and a copy of this letter will be held by the Trust.

If you have any queries related to the response provided please in the first instance contact my office.


Should you have a complaint about the response or the handling of your request, please also contact my office to request a review of this. If having exhausted the Trust's FOIA complaints process you are still not satisfied, you are entitled to approach the Information Commissioner's Office (ICO) and request an assessment of the manner in which the Trust has managed your request.

The Information Commissioner may be contacted at:

Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF or via www.ico.org.uk.

If following review of the responses I can be of any further assistance please contact my secretary on 01782 676474.

Yours,



Jean Lehnert
Information Governance Manager